Clinical, histopathological and prognostic features of primary cutaneous acral CD8


Journal

The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041

Informations de publication

Date de publication:
05 2022
Historique:
revised: 27 11 2021
received: 24 10 2021
accepted: 30 12 2021
pubmed: 7 1 2022
medline: 6 5 2022
entrez: 6 1 2022
Statut: ppublish

Résumé

The differential diagnosis of atypical dermal nonepidermotropic CD8 To assess the clinical, histological and immunophenotypic features; outcomes of; and differences between dermal CD8 Retrospective analysis of a series of 46 patients and biopsies by the international EORTC Cutaneous Lymphoma Group. The dermal CD8 A constellation of distinct clinical, histopathological and phenotypic features allows discrimination and assignment of dermal CD8

Sections du résumé

BACKGROUND
The differential diagnosis of atypical dermal nonepidermotropic CD8
OBJECTIVES
To assess the clinical, histological and immunophenotypic features; outcomes of; and differences between dermal CD8
METHODS
Retrospective analysis of a series of 46 patients and biopsies by the international EORTC Cutaneous Lymphoma Group.
RESULTS
The dermal CD8
CONCLUSIONS
A constellation of distinct clinical, histopathological and phenotypic features allows discrimination and assignment of dermal CD8

Identifiants

pubmed: 34988968
doi: 10.1111/bjd.20973
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

887-897

Informations de copyright

© 2022 British Association of Dermatologists.

Références

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC, 2017.
Kempf W, Mitteldorf C. Pathologic diagnosis of cutaneous lymphomas. Dermatol Clin 2015; 33:655-81.
Willemze R, Cerroni L, Kempf W et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood 2019; 133:1703-14.
Petrella T, Maubec E, Cornillet-Lefebvre P et al. Indolent CD8-positive lymphoid proliferation of the ear: a distinct primary cutaneous T-cell lymphoma? Am J Surg Pathol 2007; 31:1887-92.
Khamayzi Z, Ben-Arieh Y, Epelbaum R et al. Pleomorphic CD8+ small/medium size cutaneous T-cell lymphoma. Am J Dermatopathol 2006; 28:434-7.
Beltraminelli H, Mullegger R, Cerroni L. Indolent CD8+ lymphoid proliferation of the ear: a phenotypic variant of the small-medium pleomorphic cutaneous T-cell lymphoma? J Cutan Pathol 2010; 37:81-4.
Suchak R, O’Connor S, McNamara C et al. Indolent CD8-positive lymphoid proliferation on the face: part of the spectrum of primary cutaneous small-/medium-sized pleomorphic T-cell lymphoma or a distinct entity? J Cutan Pathol 2010; 37:977-81.
Kempf W, Kazakov DV, Cozzio A et al. Primary cutaneous CD8+ small to medium-sized lymphoproliferative disorder in extrafacial sites - clinicopathological features and concepts on their classification. Am J Dermatopathol 2013; 35:159-66.
Greenblatt D, Ally M, Child F et al. Indolent CD8+ lymphoid proliferation of acral sites: a clinicopathologic study of six patients with some atypical features. J Cutan Pathol 2013; 40:248-58.
Kluk J, Kai A, Koch D et al. Indolent CD8-positive lymphoid proliferation of acral sites: three further cases of a rare entity and an update on a unique patient. J Cutan Pathol 2016; 43:125-36.
Hathuc VM, Hristov AC, Smith LB. Primary cutaneous acral CD8+ T-cell lymphoma. Arch Pathol Lab Med 2017; 141:1469-75.
Tjahjono LA, Davis MDP, Witzig TE et al. Primary cutaneous acral CD8+ T-cell lymphoma - a single center review of 3 cases and recent literature review. Am J Dermatopathol 2019; 41:644-8.
Li JY, Guitart J, Pulitzer MP et al. Multicenter case series of indolent small/medium-sized CD8+ lymphoid proliferations with predilection for the ear and face. Am J Dermatopathol 2014; 36:402-8.
Swerdlow SH, Campo E, Pileri SA et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016; 127:2375-90.
Wobser M, Roth S, Reinartz T et al. CD68 expression is a discriminative feature of indolent cutaneous CD8-positive lymphoid proliferation and distinguishes this lymphoma subtype from other CD8-positive cutaneous lymphomas. Br J Dermatol 2015; 172:1573-80.
Alberti-Violetti S, Fanoni D, Provasi M et al. Primary cutaneous acral CD8 positive T-cell lymphoma with extra-cutaneous involvement: a long-standing case with an unexpected progression. J Cutan Pathol 2017; 44:964-8.
Toberer F, Christopoulos P, Lasitschka F et al. Double-positive CD8/CD4 primary cutaneous acral T-cell lymphoma. J Cutan Pathol 2019; 46:231-3.
Willemze R, Hodak E, Zinzani PL et al. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29:iv30-iv40.
Maubec E, Marinho E, Laroche L et al. Primary cutaneous acral CD8+ T-cell lymphomas relapse more frequently in younger patients. Br J Haematol 2019; 185:598-601.
Geraud C, Goerdt S, Klemke CD. Primary cutaneous CD8+ small/medium-sized pleomorphic T-cell lymphoma, ear-type: a unique cutaneous T-cell lymphoma with a favourable prognosis. Br J Dermatol 2011; 164:456-8.
Perry AM, Warnke RA, Hu Q et al. Indolent T-cell lymphoproliferative disease of the gastrointestinal tract. Blood 2013; 122:3599-606.
Plaza JA, Ortega P, Lynott J et al. CD8-positive primary cutaneous anaplastic large T-cell lymphoma (PCALCL): case report and review of this unusual variant of PCALCL. Am J Dermatopathol 2010; 32:489-91.
Magro CM, Crowson AN, Morrison C et al. CD8+ lymphomatoid papulosis and its differential diagnosis. Am J Clin Pathol 2006; 125:490-501.
Bekkenk MW, Vermeer MH, Jansen PM et al. Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood 2003; 102:2213-19.
Kempf W, Mitteldorf C, Battistella M et al. Primary cutaneous peripheral T-cell lymphoma, not otherwise specified (NOS): results of a multicentre European Organization for Research and Treatment of Cancer (EORTC) cutaneous lymphoma taskforce study on the clinico-pathological and prognostic features. J Eur Acad Dermatol Venereol 2021; 35:658-68.
Miano C, Megna M, Di Caterino P et al. An indolent nasal form of primary cutaneous CD8-positive peripheral T-cell lymphoma not otherwise specified successfully treated with local radiation therapy: a new subtype? Dermatol Ther 2021; 34:e14887.
Marzano AV, Berti E, Alessi E et al. Clonal CD8 infiltration of the skin in common variable immunodeficiency: a prelymphomatous stage? J Am Acad Dermatol 2001; 44:710-13.
Riaz IB, Faridi W, Patnaik MM et al. A systematic review on predisposition to lymphoid (B and T cell) neoplasias in patients with primary immunodeficiencies and immune dysregulatory disorders (inborn errors of immunity). Front Immunol 2019; 10:777.
Schuetz C, Huck K, Gudowius S et al. An immunodeficiency disease with RAG mutations and granulomas. N Engl J Med 2008; 358:2030-8.
Berglund LJ, Jones GJ, Murali R et al. TACI mutation with invasive polyclonal CD8+ T-cell lymphoproliferation in a patient with common variable immunodeficiency. J Allergy Clin Immunol 2006; 117:870-7.
Avitan-Hersh E, Stepensky P, Zaidman I et al. Primary cutaneous clonal CD8+ T-cell lymphoproliferative disorder associated with immunodeficiency due to RAG1 mutation. Am J Dermatopathol 2020; 42:e11-15.
Gualdi G, Lorenzi L, Arisi M et al. Acral lympho-histiocytic dermatitis in X-linked agammaglobulinemia: a case report showing clonal CD8+ T cells with indolent clinical behaviour. J Eur Acad Dermatol Venereol 2016; 30:461-3.
Gammon B, Robson A, Deonizio J et al. CD8+ granulomatous cutaneous T-cell lymphoma: a potential association with immunodeficiency. J Am Acad Dermatol 2014; 71:555-60.
Amann VC, Dreier J, Ignatova D et al. Disseminated primary cutaneous CD8+ small/medium-sized pleomorphic T-cell lymphoma responding to hydroxychloroquine. Acta Derm Venereol 2015; 95:602-3.
Lu D, Patel KA, Duvic M et al. Clinical and pathological spectrum of CD8-positive cutaneous T-cell lymphomas. J Cutan Pathol 2002; 29:465-72.

Auteurs

Werner Kempf (W)

Kempf und Pfaltz Histologische Diagnostik, Zurich, Switzerland.
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.

Tony Petrella (T)

Department of Pathology, Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada.

Rein Willemze (R)

Department of Dermatology.

Patty Jansen (P)

Department of Clinical Pathology, Leiden University Medical Center, Leiden, the Netherlands.

Emilio Berti (E)

University of Milan, Director U.O.C. of Dermatology Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico of Milan, Milan, Italy.

Marco Santucci (M)

Department of Health Sciences, University of Florence School of Human Health Sciences and Division of Histopathology and Molecular Diagnostics, Careggi University Hospital, Florence, Italy.

Eva Geissinger (E)

Institute of Pathology, University of Würzburg, Würzburg, Germany.

Lorenzo Cerroni (L)

Department of Dermatology, Medical University of Graz, Graz, Austria.

Eve Maubec (E)

Service de Dermatologie du Pr F. Caux, Hôpital Avicenne, Bobigny, CEDEX, France.

Maxime Battistella (M)

Department of Pathology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, Paris University, INSERM U976, Paris, France.

John Goodlad (J)

NHS Greater Glasgow and Clyde, Glasgow, UK.

Emmanuella Guenova (E)

Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
Department of Dermatology, University Hospital Lausanne, Faculty of Biology and Medicine, University of Lausanne, CH-1011, Lausanne, Switzerland.

Katariina Lappalainen (K)

Skin and Allergy Hospital, Helsinki University Central Hospital, Helsinki, Finland.

Annamari Ranki (A)

Skin and Allergy Hospital, Helsinki University Central Hospital, Helsinki, Finland.

Paul Craig (P)

Gloucestershire Hospitals NHS Foundation Trust, Gloucestershire Cellular Pathology Laboratory, Cheltenham General Hospital, Cheltenham, UK.

Eduardo Calonje (E)

Department of Dermatopathology, St John's Institute of Dermatology, St Thomas' Hospital, London, UK.

Blanca Martin (B)

Department of Dermatopathology, St John's Institute of Dermatology, St Thomas' Hospital, London, UK.

Sean Whittaker (S)

St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust, London, UK.

Ilske Oschlies (I)

Department of Pathology, Section Hematopathology and Lymph Node Registry, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.

Ulrike Wehkamp (U)

Department of Dermatology and Allergology, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.

Jan P Nicolay (JP)

Department of Dermatology, University Medical Center Mannheim, Mannheim, Germany.

Marion Wobser (M)

Department of Dermatology, Venereology and Allergology and Skin Cancer Center, University Hospital Würzburg, Würzburg, Germany.

Julia Scarisbruck (J)

Department of Dermatology, University Hospital Birmingham, Birmingham, UK.

Nicola Pimpinelli (N)

Dermatology Unit, Department of Health Sciences, University of Florence Medical School, Florence, Italy.

Rudi Stadler (R)

Department of Dermatology, Venerology, Allergology and Phlebology, Johannes Wesling Klinikum Minden, University Clinic Ruhr-Universität Bochum, Minden, Germany.

Katrin Kerl French (K)

Department of Dermatology, Ludwig-Maximilian University Hospital of Munich, Munich, Germany.

Pietro Quaglino (P)

Dermatologic Clinic, Department of Medical Sciences, University of Turin Medical School, Torino, Italy.

Jinran Lin (J)

Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.

Lianjun Chen (L)

Department of Dermatology, Huashan Hospital, Fudan University, Shanghai, China.

Michaela Beer (M)

Kempf und Pfaltz Histologische Diagnostik, Zurich, Switzerland.

Patrick Emanuel (P)

Clinica Ricarda Palma, Lima, Peru.
University of Auckland, Auckland, New Zealand.

Stephane Dalle (S)

Unit of Dermatology, Cancer Research Centre of Lyon, Hôpital Lyon Sud, Hospices Civils de Lyon, Université Claude Bernard, Lyon 1, France.

Alistair Robson (A)

Institute of Oncology, Lisbon, Portugal.
LDPath, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH